International Assets Investment Management LLC Has $336,000 Stake in AstraZeneca PLC (NASDAQ:AZN)

International Assets Investment Management LLC cut its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 98.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,106 shares of the company’s stock after selling 278,555 shares during the quarter. International Assets Investment Management LLC’s holdings in AstraZeneca were worth $336,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. Martin Investment Management LLC increased its stake in shares of AstraZeneca by 2.8% during the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock worth $22,571,000 after purchasing an additional 7,615 shares during the period. Integrated Advisors Network LLC lifted its holdings in shares of AstraZeneca by 46.6% during the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock worth $3,398,000 after buying an additional 13,860 shares in the last quarter. Creative Planning boosted its position in shares of AstraZeneca by 8.0% in the third quarter. Creative Planning now owns 224,751 shares of the company’s stock valued at $17,510,000 after acquiring an additional 16,692 shares during the period. Soros Fund Management LLC grew its stake in shares of AstraZeneca by 8.2% in the third quarter. Soros Fund Management LLC now owns 2,652,771 shares of the company’s stock valued at $206,677,000 after acquiring an additional 201,233 shares in the last quarter. Finally, Optas LLC increased its position in AstraZeneca by 173.5% during the third quarter. Optas LLC now owns 15,570 shares of the company’s stock worth $1,213,000 after acquiring an additional 9,877 shares during the period. Institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on AZN shares. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Stock Performance

Shares of AstraZeneca stock opened at $67.01 on Friday. The company has a 50 day moving average of $66.11 and a 200-day moving average of $74.89. The company has a market cap of $207.77 billion, a PE ratio of 32.06, a price-to-earnings-growth ratio of 1.19 and a beta of 0.46. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter last year, the business posted $0.87 EPS. The company’s revenue was up 18.0% compared to the same quarter last year. As a group, equities research analysts forecast that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.